Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | 2C34H37N5O5.C4H6O6 |
| Molecular Weight | 1341.463 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 14 / 14 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@H]([C@@H](O)C(O)=O)C(O)=O.[H][C@@]12CCCN1C(=O)[C@H](CC3=CC=CC=C3)N4C(=O)[C@](C)(NC(=O)[C@H]5CN(C)[C@]6([H])CC7=CN(C)C8=CC=CC(=C78)C6=C5)O[C@@]24O.[H][C@@]9%10CCCN9C(=O)[C@H](CC%11=CC=CC=C%11)N%12C(=O)[C@](C)(NC(=O)[C@H]%13CN(C)[C@]%14([H])CC%15=CN(C)C%16=CC=CC(=C%15%16)C%14=C%13)O[C@@]%10%12O
InChI
InChIKey=JNLPZFZYKSNPFF-DGEBZBOOSA-N
InChI=1S/2C34H37N5O5.C4H6O6/c2*1-33(32(42)39-27(15-20-9-5-4-6-10-20)31(41)38-14-8-13-28(38)34(39,43)44-33)35-30(40)22-16-24-23-11-7-12-25-29(23)21(18-36(25)2)17-26(24)37(3)19-22;5-1(3(7)8)2(6)4(9)10/h2*4-7,9-12,16,18,22,26-28,43H,8,13-15,17,19H2,1-3H3,(H,35,40);1-2,5-6H,(H,7,8)(H,9,10)/t2*22-,26-,27+,28+,33-,34+;1-,2-/m111/s1
| Molecular Formula | C4H6O6 |
| Molecular Weight | 150.0868 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | C34H37N5O5 |
| Molecular Weight | 595.6881 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Metergotamine (MY-25 or 1-methyl-ergotamine-bitartrate) is a derivative of ergotamine and belongs to peptide alkaloids. It exerts a dampening effect on vessels, in that relaxation is brought about in contracted vessels, whereas contraction is brought in dilated vessels. Metergotamine was being studied in migraine prophylaxis.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| [MY 25, a peroral prophylactic for migraine]. | 1971 Jun 25 |
|
| Clinical trial of MY-25 (1-methyl-ergotamine-bitartrate) in migraine prophylaxis. | 1971 Oct |
|
| Comparative pharmacokinetic investigations with tritium-labeled ergot alkaloids after oral and intravenous administration man. | 1977 Mar |
|
| Preparedness of Dammam primary health care centers to deal with emergency cases. | 2017 Sep-Dec |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 12:37:28 UTC 2023
by
admin
on
Sat Dec 16 12:37:28 UTC 2023
|
| Record UNII |
BA69AZP187
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
16891-52-4
Created by
admin on Sat Dec 16 12:37:29 UTC 2023 , Edited by admin on Sat Dec 16 12:37:29 UTC 2023
|
PRIMARY | |||
|
123133553
Created by
admin on Sat Dec 16 12:37:29 UTC 2023 , Edited by admin on Sat Dec 16 12:37:29 UTC 2023
|
PRIMARY | |||
|
BA69AZP187
Created by
admin on Sat Dec 16 12:37:29 UTC 2023 , Edited by admin on Sat Dec 16 12:37:29 UTC 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |